📚 Part of the TILA-278 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.

---

Project Charter (TILA-278)

Document ID: PM-001
Version: 1.0
Change History: 1.0 — Initial issue.
Standard(s): Program management

Project Charter — TILA-278

Authorises the TILA-278 development project (sponsor Virtual Biopharma Inc.): objectives, scope, the pivotal study TILA278-201, key milestones, budget envelope, governance, and success criteria tied to the target product profile.

1. Purpose and Authorization

This Charter formally authorizes the TILA-278 development program and establishes the mandate, boundaries, and accountability under which the cross-functional program team operates. TILA-278 is being advanced by Virtual Biopharma Inc. as a novel biologic for the treatment of adults with moderately-to-severely active ulcerative colitis (UC). The Charter is the controlling reference for program scope decisions and for the allocation of resources across Nonclinical, Chemistry Manufacturing and Controls (CMC), Clinical, Clinical Pharmacology, Regulatory Affairs, Biostatistics, Pharmacovigilance, and Program Management. It is issued in support of the eventual Biologics License Application (BLA) submitted under Section 351(a) of the Public Health Service Act and 21 CFR Part 601. Changes to program scope, the target label, or the registrational strategy require re-approval of this Charter by the Development Governance Committee.

2. Background and Therapeutic Rationale

Ulcerative colitis is a chronic, relapsing, immune-mediated inflammatory disease of the colonic mucosa characterized by rectal bleeding, urgency, increased stool frequency, and progressive mucosal damage. Despite the availability of anti-TNF agents, anti-integrin therapy, anti-IL-12/23 and selective JAK inhibitors, a substantial fraction of patients fail to achieve or maintain corticosteroid-free clinical and endoscopic remission, and durability, safety, and tolerability limitations persist across the current armamentarium. A meaningful unmet need therefore remains for therapies that simultaneously suppress pathogenic mucosal inflammation and actively restore epithelial barrier integrity.

TILA-278 addresses this need through a differentiated dual-pathway mechanism. TNF-like ligand 1A (TL1A, TNFSF15) is an established driver of mucosal inflammation and intestinal fibrosis in inflammatory bowel disease; its neutralization is anticipated to produce both anti-inflammatory and anti-fibrotic effects. Interleukin-22 (IL-22) signaling through its epithelial receptor (IL-22RA1) promotes epithelial proliferation, antimicrobial peptide production, mucin secretion, and mucosal wound healing. The scientific hypothesis underpinning the program is that combining TL1A antagonism with IL-22 receptor agonism in a single molecule will deliver deeper and more durable disease control than pathway-selective agents by concurrently dampening the inflammatory drive and accelerating restitution of the epithelial barrier.

3. Product Description and Mechanism of Action

TILA-278 is a humanized, bispecific IgG1 monoclonal antibody produced in Chinese hamster ovary (CHO) cell culture and administered by subcutaneous injection. The molecule pairs two independent binding specificities in a single heterodimeric IgG1 scaffold: one arm functions as an antagonist of TL1A, blocking ligand engagement of death receptor 3 (DR3) and thereby interrupting downstream pro-inflammatory and pro-fibrotic signaling; the second arm functions as an agonist at the IL-22 receptor, delivering a mucosal-healing signal that recapitulates the protective epithelial effects of IL-22. The asymmetric bispecific architecture is enabled by heterodimerization engineering of the Fc region to ensure correct chain pairing and a homogeneous product.

The opposing pharmacology of the two arms — antagonism on one target and agonism on the other — is the defining design feature of the program and shapes the entire nonclinical and clinical pharmacology strategy, including target-mediated drug disposition (TMDD) considerations, dose selection, and receptor-occupancy characterization for each specificity independently.

4. Target Product Profile (TPP)

• Indication: Induction and maintenance of clinical remission in adults with moderately-to-severely active ulcerative colitis, including patients who are biologic-naïve and those with prior inadequate response, loss of response, or intolerance to conventional or advanced therapies.
• Modality: Humanized bispecific IgG1 monoclonal antibody (anti-TL1A antagonist × IL-22R agonist), CHO-derived.
• Route and presentation: Subcutaneous administration; high-concentration liquid presentation intended to support a patient- or caregiver-administered maintenance regimen following induction.
• Efficacy positioning: Superiority to placebo on clinical remission and endoscopic improvement, with a differentiated mucosal-healing profile attributable to IL-22R agonism and an anti-fibrotic benefit attributable to TL1A antagonism.
• Safety positioning: Tolerability and immunogenicity profile consistent with a subcutaneously administered therapeutic monoclonal antibody, with manageable injection-site reactions and low clinically meaningful anti-drug antibody (ADA) impact.
• Regulatory objective: BLA licensure under 21 CFR Part 601, with a clinical dossier structured to support both induction and maintenance claims.

5. Development Objectives and Scope

The program objectives are to: (i) confirm the clinical efficacy and safety of TILA-278 in moderately-to-severely active UC; (ii) establish the commercial CHO manufacturing process and control strategy to registrational standard; (iii) complete the nonclinical safety package appropriate to a biotechnology-derived bispecific antibody; (iv) characterize human pharmacokinetics, pharmacodynamics, immunogenicity, and exposure–response to support dose selection; and (v) assemble and submit a BLA supporting licensure for induction and maintenance of remission.

In scope: nonclinical pharmacology, safety pharmacology as integrated into repeat-dose toxicology, PK/TMDD and immunogenicity characterization, the Phase 2b dose-ranging study TILA278-201, the confirmatory Phase 3 induction and maintenance program, CMC development and process validation, and regulatory interactions through licensure. Out of scope for this Charter: pediatric development beyond the agreed initial pediatric study plan, indications outside UC, and lifecycle line extensions, each of which will be governed under separate authorization.

6. Pivotal Evidence — Study TILA278-201

Study TILA278-201 is a Phase 2b, randomized, double-blind, placebo-controlled, parallel-group study evaluating a 12-week induction course of TILA-278 in adults with moderately-to-severely active UC. Participants were randomized 1:1:1 to a High dose, a Low dose, or placebo. Of 1,700 patients screened, 900 were randomized (299 High, 300 Low, 301 Placebo), and the Full Analysis Set (FAS) comprised 840 patients (284 High, 283 Low, 273 Placebo). The study establishes proof of concept, characterizes the dose–response relationship, and informs Phase 3 dose selection.

Primary endpoint — clinical remission at Week 12 (modified Mayo score ≤ 2 with no individual subscore > 1):

Arm	Clinical remission at Week 12
High dose	37.3% (106/284)
Low dose	16.2% (46/283)
Placebo	0.7% (2/273)

Both active doses were superior to placebo on the primary endpoint, with a clear monotonic dose–response (High > Low > Placebo) supporting the mechanistic hypothesis.

Key secondary endpoints:

• Change from baseline in modified Mayo score at Week 12 (LS-mean): −3.36 (High), −2.76 (Low), −1.00 (Placebo); LS-mean difference versus placebo of −2.36 (High) and −1.77 (Low).
• Endoscopic improvement at Week 12: 48.9% (High), 27.9% (Low), 6.2% (Placebo).

The endoscopic improvement gradient is consistent with the mucosal-healing rationale for IL-22R agonism, and the composite of clinical remission and endoscopic benefit provides an internally consistent efficacy signal supporting progression to a confirmatory Phase 3 program. Safety, tolerability, injection-site reactions, and immunogenicity (ADA incidence and impact on exposure and response) are assessed as supportive study objectives and feed directly into the benefit–risk framing for later phases.

7. Chemistry, Manufacturing and Controls (CMC) Strategy

TILA-278 drug substance is manufactured by fed-batch CHO cell culture followed by a platform-aligned purification train comprising Protein A affinity capture and orthogonal polishing steps, with dedicated viral clearance operations. The control strategy addresses the product-quality attributes characteristic of a heterodimeric bispecific IgG1, including correct chain pairing, mispairing and half-antibody species, charge and size heterogeneity, glycosylation, and potency against both the TL1A-antagonist and IL-22R-agonist functions. Release and stability specifications are established in accordance with ICH Q6B, and drug substance and drug product stability programs are designed per ICH Q5C. Viral safety of the cell-substrate-derived product is assured under ICH Q5A(R2), covering testing, process clearance evaluation, and the overall viral safety strategy. The subcutaneous route and intended self-administration drive a high-concentration formulation and container-closure/device strategy, with associated viscosity, aggregation, and injectability considerations built into formulation development and comparability planning.

8. Nonclinical Development Strategy

The nonclinical program is conducted in accordance with ICH S6(R1) for biotechnology-derived pharmaceuticals. The cynomolgus monkey is the sole pharmacologically relevant toxicology species, justified by demonstrated cross-reactivity and functional pharmacology at both the TL1A and IL-22R targets; rodents are not pharmacologically relevant to the human targets and are therefore not used for pivotal toxicology. Safety pharmacology endpoints are integrated into the repeat-dose toxicology studies rather than conducted as stand-alone studies, consistent with S6(R1). Consistent with the large-molecule modality and current regulatory expectations, standard genotoxicity, carcinogenicity, and hERG/thorough-QT cardiac safety assessments are not warranted and are not included in the program; the cardiovascular assessment is addressed within the general toxicology and clinical safety evaluations. Tissue cross-reactivity, immunogenicity characterization, and the TMDD-informed toxicokinetic strategy round out the nonclinical package supporting first-in-human and later-phase dosing.

9. Clinical Pharmacology Strategy

The clinical pharmacology plan characterizes the pharmacokinetics of a subcutaneously administered bispecific antibody exhibiting target-mediated drug disposition, including the potential for nonlinear, dose-dependent clearance driven by engagement of TL1A and the IL-22 receptor. Objectives include definition of the PK profile and bioavailability, population PK modeling, receptor-occupancy and pharmacodynamic biomarker characterization for each specificity, immunogenicity (ADA and neutralizing antibody) assessment and its impact on exposure, safety, and efficacy, and exposure–response analyses linking the TILA278-201 dose arms to the primary and key secondary endpoints. These analyses provide the quantitative basis for Phase 3 dose confirmation and for the induction-to-maintenance transition strategy.

10. Regulatory Strategy

The program targets licensure via a BLA under Section 351(a) of the PHS Act and 21 CFR Part 601. The governing quality and nonclinical guidance set comprises ICH Q5A(R2) (viral safety), ICH Q5C (biologic stability), ICH Q6B (specifications for biotechnological/biological products), and ICH S6(R1) (preclinical safety evaluation of biotechnology-derived pharmaceuticals). The regulatory plan includes structured Health Authority engagement at key development milestones (End-of-Phase 2 interaction to align on the Phase 3 design and registrational endpoints, and pre-BLA interactions to align on the content and format of the marketing application), an agreed pediatric strategy, and a lifecycle safety and immunogenicity monitoring plan. The bispecific, dual-mechanism nature of the molecule is reflected in dedicated comparability, potency, and characterization commitments within the regulatory dossier.

11. Program Governance

The program operates under a two-tier governance structure. The Development Governance Committee (executive sponsorship, functional heads) holds decision authority over phase-gate progression, registrational strategy, and budget. The Core Program Team, led by the Program Lead, executes day-to-day cross-functional delivery across Nonclinical, CMC, Clinical, Clinical Pharmacology, Biostatistics, Regulatory Affairs, Pharmacovigilance, and Program Management. Decision rights, escalation paths, and phase-gate criteria are defined for each major transition (candidate confirmation, End-of-Phase 2, Phase 3 start, pre-BLA, and BLA submission). Risk, quality, and safety oversight are standing agenda items, with an independent safety review function supporting the clinical program.

12. Key Milestones

• M1 — Nonclinical package complete: Cynomolgus repeat-dose toxicology, TMDD toxicokinetics, and immunogenicity characterization supporting confirmatory dosing.
• M2 — Phase 2b readout (TILA278-201): Confirmation of dose–response on clinical remission and endoscopic improvement (achieved per Section 6).
• M3 — End-of-Phase 2 Health Authority interaction: Alignment on Phase 3 design, endpoints, and dose selection.
• M4 — Phase 3 induction and maintenance program initiation.
• M5 — Commercial process validation and registrational CMC package.
• M6 — BLA submission under 21 CFR Part 601.
• M7 — Licensure and launch readiness.

Milestone dates and phase-gate criteria are maintained in the integrated program plan and are subject to governance review at each transition.

13. Budget Envelope

An approved, phase-gated budget envelope funds the program from Phase 2b completion through BLA submission, allocated across Nonclinical, CMC (including commercial process development and validation), the Phase 3 induction and maintenance program, Clinical Pharmacology, Regulatory, and Pharmacovigilance. Funding is released against successful passage of each phase gate; material variance to the envelope or reallocation across functions requires Development Governance Committee approval. Detailed cost breakdowns and resourcing plans are maintained under separate financial control documents referenced by this Charter.

14. Success Criteria

The program is considered successful when it delivers: (i) a confirmatory Phase 3 demonstration of efficacy and safety in moderately-to-severely active UC consistent with the proof-of-concept established in TILA278-201; (ii) a validated CHO manufacturing process and control strategy meeting ICH Q5A(R2)/Q5C/Q6B expectations; (iii) a nonclinical safety package compliant with ICH S6(R1) using the cynomolgus monkey as the sole relevant species; (iv) a characterized clinical pharmacology, TMDD PK, and immunogenicity profile supporting the registrational dose and regimen; and (v) a BLA accepted for review under 21 CFR Part 601 supporting the target product profile.

15. Key Risks and Mitigations

• Immunogenicity / ADA impact on exposure and response: Mitigated by humanized IgG1 design, comprehensive ADA and neutralizing-antibody assessment, and exposure–response monitoring across phases.
• Bispecific product-quality complexity (chain mispairing, half-antibody, heterogeneity): Mitigated by Fc heterodimerization engineering, orthogonal polishing, dual-function potency assays, and an ICH Q6B-aligned specification and comparability strategy.
• TMDD-driven nonlinear PK complicating dose selection: Mitigated by population PK modeling, receptor-occupancy characterization for each arm, and integrated exposure–response analysis.
• Manufacturing scale-up and high-concentration subcutaneous formulation risk: Mitigated by early formulation/device development, comparability planning, and staged process validation.
• Single relevant toxicology species (cynomolgus): Managed within ICH S6(R1) expectations, with scientific justification of species relevance and integrated safety pharmacology.
• Confirmatory efficacy risk in Phase 3: Mitigated by the clear Phase 2b dose–response, endpoint alignment through End-of-Phase 2 interaction, and evidence-based dose selection.